The clinical value of progestin-primed ovarian stimulation protocol for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis.
clomiphene
diminished ovarian reserve
in vitro fertilization
intracytoplasmic sperm injection
letrozole
progestin-primed ovarian stimulation
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
06
2023
accepted:
26
07
2023
medline:
7
9
2023
pubmed:
6
9
2023
entrez:
6
9
2023
Statut:
epublish
Résumé
To determine whether progestin-primed ovarian stimulation (PPOS) is more effective for women with diminished ovarian reserve (DOR) than clomiphene citrate (CC)/letrozole (LE) plus gonadotropin in IVF or ICSI treatment. Nine databases were searched until May 24, 2023, to identify relevant studies. Forest plots were used to present the results of this meta-analysis. Begg's and Egger's tests were applied to estimate publication bias. Subgroup and sensitivity analysis were performed to check the potential sources of heterogeneity and verify the robustness of the pooled results, respectively. A total of 14 studies with 4182 participants were included for meta-analysis. There was evidence of a statistically notable increase in clinical pregnancy rate (OR = 1.39, 95%CI [1.01, 1.91], Based on evidence-based results, PPOS protocol seems to improve IVF/ICSI outcomes for women with DOR. More research with larger sample sizes and rigorous designs are required to further explore the value of PPOS among women diagnosed with DOR. www.crd.york.ac.uk, identifier CRD42023430202.
Sections du résumé
Background
To determine whether progestin-primed ovarian stimulation (PPOS) is more effective for women with diminished ovarian reserve (DOR) than clomiphene citrate (CC)/letrozole (LE) plus gonadotropin in IVF or ICSI treatment.
Methods
Nine databases were searched until May 24, 2023, to identify relevant studies. Forest plots were used to present the results of this meta-analysis. Begg's and Egger's tests were applied to estimate publication bias. Subgroup and sensitivity analysis were performed to check the potential sources of heterogeneity and verify the robustness of the pooled results, respectively.
Results
A total of 14 studies with 4182 participants were included for meta-analysis. There was evidence of a statistically notable increase in clinical pregnancy rate (OR = 1.39, 95%CI [1.01, 1.91],
Conclusions
Based on evidence-based results, PPOS protocol seems to improve IVF/ICSI outcomes for women with DOR. More research with larger sample sizes and rigorous designs are required to further explore the value of PPOS among women diagnosed with DOR.
Systematic review registration
www.crd.york.ac.uk, identifier CRD42023430202.
Identifiants
pubmed: 37670890
doi: 10.3389/fendo.2023.1232935
pmc: PMC10476097
doi:
Substances chimiques
Progestins
0
Steroids
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1232935Informations de copyright
Copyright © 2023 Lin, Zhong, Li, Liu and Xu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hum Reprod. 2007 Jun;22(6):1506-12
pubmed: 17376819
Hum Reprod. 2011 Jul;26(7):1616-24
pubmed: 21505041
Fertil Steril. 2021 Apr;115(4):966-973
pubmed: 33583594
Reproduction. 2010 Oct;140(4):559-68
pubmed: 20634390
Hum Reprod Update. 2021 Feb 19;27(2):229-253
pubmed: 33146690
Fertil Steril. 2015 Nov;104(5):1145-52.e1-5
pubmed: 26297646
J Assist Reprod Genet. 2015 Dec;32(12):1709-12
pubmed: 26463876
Front Endocrinol (Lausanne). 2022 Jul 25;13:904089
pubmed: 35957830
Trends Endocrinol Metab. 2023 Apr;34(4):194-215
pubmed: 36863888
Front Endocrinol (Lausanne). 2023 Apr 18;14:1117513
pubmed: 37143731
J Reprod Med. 2017 Mar-Apr;62(3-4):153-60
pubmed: 30230307
Front Endocrinol (Lausanne). 2022 May 19;13:837880
pubmed: 35663329
Front Endocrinol (Lausanne). 2019 Nov 22;10:796
pubmed: 31824419
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Hum Reprod Open. 2018 Apr 25;2018(3):hoy006
pubmed: 30895247
Hum Reprod Update. 2015 Jul-Aug;21(4):411-26
pubmed: 25801630
J Chin Med Assoc. 2019 Nov;82(11):845-848
pubmed: 31453864
Drug Des Devel Ther. 2019 Jul 26;13:2553-2563
pubmed: 31440037
Hum Reprod. 2021 Mar 18;36(4):987-997
pubmed: 33367742
Front Endocrinol (Lausanne). 2022 Jan 24;12:801026
pubmed: 35140685
J Endocrinol. 2015 Sep;226(3):167-80
pubmed: 26264981
Environ Int. 2019 Jul;128:390-398
pubmed: 31078873
Eur J Obstet Gynecol Reprod Biol. 2022 Sep;276:228-235
pubmed: 35952470
Fertil Steril. 2015 Jul;104(1):62-70.e3
pubmed: 25956370
Fertil Steril. 2015 Sep;104(3):612-19.e3
pubmed: 26049057
Hum Reprod. 2020 Jun 1;35(6):1325-1331
pubmed: 32395749
Front Endocrinol (Lausanne). 2021 Aug 31;12:702558
pubmed: 34531825
J Assist Reprod Genet. 2023 Jun;40(6):1467-1477
pubmed: 37145374
JAMA. 2021 Jul 06;326(1):65-76
pubmed: 34228062
Sci Rep. 2017 Jan 03;7:39912
pubmed: 28045093
Aging (Albany NY). 2021 Mar 26;13(7):10128-10140
pubmed: 33819190
Reprod Biomed Online. 2020 Jun;40(6):894-903
pubmed: 32327297
Front Endocrinol (Lausanne). 2021 Feb 22;12:635370
pubmed: 33692760
Hum Reprod Update. 2020 Jan 1;26(1):118-135
pubmed: 31867625